|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
King SC, Pollack LA, Li J, King JB and
Master VA: Continued increase in incidence of renal cell carcinoma
especially in young patients and high grade disease: United States
2001 to 2010. J Urol. 191:1665–1670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lipworth L, Tarone RE and McLaughlin JK:
The epidemiology of renal cell carcinoma. J Urol. 176:2353–2358.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Banegas MP, Harlan LC, Mann B and Yabroff
KR: Renal cell cancer: A shift in approaches for treatment of
advanced disease in the United States. J Natl Compr Canc Netw.
12:1271–1279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sunela KL, Lehtinen ET, Kataja MJ, Kujala
PM, Soimakallio S and Kellokumpu-Lehtinen PL: Development of renal
cell carcinoma (RCC) diagnostics and impact on prognosis. BJU Int.
113:228–235. 2014. View Article : Google Scholar
|
|
6
|
Roy B, Pattanaik AK, Das J, Bhutia SK,
Behera B, Singh P and Maiti TK: Role of PI3K/Akt/mTOR and MEK/ERK
pathway in Concanavalin A induced autophagy in HeLa cells. Chem
Biol Interact. 210:96–102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ersahin T, Tuncbag N and Cetin-Atalay R:
The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 11:1946–1954.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar
|
|
9
|
Guo H, German P, Bai S, Barnes S, Guo W,
Qi X, Lou H, Liang J, Jonasch E, Mills GB, et al: The PI3K/AKT
pathway and renal cell carcinoma. J Genet Genomics. 42:343–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu F, Wu S and Gou X: Identification of
biomarkers and potential molecular mechanisms of clear cell renal
cell carcinoma. Neoplasma. 65:242–252. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dickson GJ, Kwasniewska A, Mills KI,
Lappin TR and Thompson A: Hoxa6 potentiates short-term hemopoietic
cell proliferation and extended self-renewal. Exp Hematol.
37:322–333. e3232009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo YB, Shao YM, Chen J, Xu SB, Zhang XD,
Wang MR and Liu HY: Effect of overexpression of HOX genes on its
invasive tendency in cerebral glioma. Oncol Lett. 11:75–80. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Liu Y, Yan L, Zhang M, Yu X, Du
W, Wang S, Li Q, Chen H, Zhang Y, et al: Increased levels of the
long noncoding RNA, HOXA-AS3, promote proliferation of A549 cells.
Cell Death Dis. 9:7072018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu S, Wu F and Jiang Z: Effect of HOXA6 on
the proliferation, apoptosis, migration and invasion of colorectal
cancer cells. Int J Oncol. 52:2093–2100. 2018.PubMed/NCBI
|
|
15
|
Eoh KJ, Kim HJ, Lee J-Y, Nam EJ, Kim S,
Kim SW and Kim YT: Upregulation of homeobox gene is correlated with
poor survival outcomes in cervical cancer. Oncotarget.
8:84396–84402. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xavier FC, Destro MF, Duarte CM and Nunes
FD: Epigenetic repression of HOXB cluster in oral cancer cell
lines. Arch Oral Biol. 59:783–789. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Galani V, Lampri E, Varouktsi A, Alexiou
G, Mitselou A and Kyritsis AP: Genetic and epigenetic alterations
in meningiomas. Clin Neurol Neurosurg. 158:119–125. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hur H, Lee JY, Yun HJ, Park BW and Kim MH:
Analysis of HOX gene expression patterns in human breast cancer.
Mol Biotechnol. 56:64–71. 2014. View Article : Google Scholar
|
|
19
|
Gumz ML, Zou H, Kreinest PA, Childs AC,
Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et
al: Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin Cancer Res.
13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tun HW, Marlow LA, von Roemeling CA,
Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ and
Copland JA: Pathway signature and cellular differentiation in clear
cell renal cell carcinoma. PLoS One. 5:e106962010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; New York, NY: pp. 547–560. 2010
|
|
22
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45(W1):
W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
24
|
Ishiyama M, Miyazono Y, Sasamoto K, Ohkura
Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt
as a chro-mogenic indicator for NADH as well as cell viability.
Talanta. 44:1299–1305. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar
|
|
26
|
Rafehi H, Orlowski C, Georgiadis GT,
Ververis K, El-Osta A and Karagiannis TC: Clonogenic assay:
Adherent cells. J Vis Exp. (49): 25732011.PubMed/NCBI
|
|
27
|
Salic A and Mitchison TJ: A chemical
method for fast and sensitive detection of DNA synthesis in vivo.
Proc Natl Acad Sci USA. 105:2415–2420. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pierzyńska-Mach A, Szczurek A, Cella
Zanacchi F, Pennacchietti F, Drukała J, Diaspro A, Cremer C,
Darzynkiewicz Z and Dobrucki JW: Subnuclear localization, rates and
effectiveness of UVC-induced unscheduled DNA synthesis visualized
by fluorescence widefield, confocal and super-resolution
microscopy. Cell Cycle. 15:1156–1167. 2016. View Article : Google Scholar
|
|
29
|
Gavrieli Y, Sherman Y and Ben-Sasson SA:
Identification of programmed cell death in situ via specific
labeling of nuclear DNA fragmentation. J Cell Biol. 119:493–501.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Szeberenyl J: Analysis of the cell cycle
by flow cytometry. Biochem Mol Biol Educ. 35:153–154. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Riccardi C and Nicoletti I: Analysis of
apoptosis by propidium iodide staining and flow cytometry. Nat
Protoc. 1:1458–1461. 2006. View Article : Google Scholar
|
|
32
|
Worby CA and Dixon JE: Pten Annu Rev
Biochem. 83:641–669. 2014. View Article : Google Scholar
|
|
33
|
Hopkins BD, Hodakoski C, Barrows D, Mense
SM and Parsons RE: PTEN function: The long and the short of it.
Trends Biochem Sci. 39:183–190. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wyatt LA, Filbin MT and Keirstead HS: PTEN
inhibition enhances neurite outgrowth in human embryonic stem
cell-derived neuronal progenitor cells. J Comp Neurol.
522:2741–2755. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hemmings BA and Restuccia DF: PI3K-PKB/Akt
pathway. Cold Spring Harb Perspect Biol. 4:a0111892012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meloche S and Pouysségur J: The ERK1/2
mitogen-activated protein kinase pathway as a master regulator of
the G1- to S-phase transition. Oncogene. 26:3227–3239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao Y and Adjei AA: The clinical
development of MEK inhibitors. Nat Rev Clin Oncol. 11:385–400.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Neuzillet C, Tijeras-Raballand A, de
Mestier L, Cros J, Faivre S and Raymond E: MEK in cancer and cancer
therapy. Pharmacol Ther. 141:160–171. 2014. View Article : Google Scholar
|
|
39
|
Yang T, Xu F, Sheng Y, Zhang W and Chen Y:
A targeted proteomics approach to the quantitative analysis of
ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in
breast cancer. Anal Bioanal Chem. 408:7491–7503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zeren T, Inan S, Vatansever HS and Sayhan
S: Significance of apoptosis related proteins on malignant
transformation of ovarian tumors: A comparison between Bcl-2/Bax
ratio and p53 immunoreactivity. Acta Histochem. 116:1251–1258.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Samarghandian S, Nezhad MA and Mohammadi
G: Role of caspases, Bax and Bcl-2 in chrysin-induced apoptosis in
the A549 human lung adenocarcinoma epithelial cells. Anticancer
Agents Med Chem. 14:901–909. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brentnall M, Rodriguez-Menocal L, De
Guevara RL, Cepero E and Boise LH: Caspase-9, caspase-3 and
caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell
Biol. 14:322013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Boulares AH, Yakovlev AG, Ivanova V,
Stoica BA, Wang G, Iyer S and Smulson M: Role of poly(ADP-ribose)
polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP
mutant increases rates of apoptosis in transfected cells. J Biol
Chem. 274:22932–22940. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mullen P: PARP cleavage as a means of
assessing apoptosis. Methods Mol Med. 88:171–181. 2004.
|
